Duchenne Drug Dispute: Capricor Therapeutics vs. Nippon Shinyaku – Key Questions Answered

Capricor Therapeutics has filed a lawsuit against Nippon Shinyaku and its U.S. subsidiary NS Pharma, accusing them of failing to execute marketing plans for a Duchenne muscular dystrophy treatment and refusing to fix a pricing flaw in their exclusive distribution agreement. This Q&A explores the key issues surrounding the dispute.

• What is the lawsuit about?
• What is the 'fatal flaw' in the pricing formula?
• How does this pricing issue affect patient access?
• What is deramiocel, and why is it important?
• What are the specific allegations against Nippon Shinyaku?
• What does Capricor Therapeutics want from this lawsuit?

What is the lawsuit about?

Capricor Therapeutics filed a lawsuit in a New Jersey state court on Thursday, accusing Nippon Shinyaku and its U.S. subsidiary NS Pharma of slow-walking marketing plans for a Duchenne muscular dystrophy treatment called deramiocel. The central issue is a fatal flaw in the exclusive distribution agreement’s pricing formula, which Capricor claims makes it economically impracticable for the therapy to reach patients covered by Medicare, Medicaid, and private insurers. Capricor alleges that Nippon Shinyaku refuses to fix this glitch, despite knowing about it since March 2025. The dispute threatens to delay or block access to a promising treatment for Duchenne patients.

What is the 'fatal flaw' in the pricing formula?

The lawsuit identifies a fatal flaw in the pricing formula embedded in the exclusive distribution agreement. Under the deal, NS Pharma is the sole U.S. buyer of deramiocel, and the formula ties Medicare and Medicaid reimbursement directly to the price Capricor charges NS Pharma. However, as currently structured, healthcare providers would receive reimbursements lower than their actual costs for acquiring and administering the drug. This means hospitals and clinics would lose money on every dose, making them reluctant or unable to offer the therapy. Capricor argues that this flaw was belatedly discovered and that Nippon Shinyaku has refused to amend the contract to fix it, effectively slow-walking the drug’s launch.

How does this pricing issue affect patient access?

The pricing glitch directly impacts patient access because it creates a disincentive for healthcare providers to purchase and administer deramiocel. If providers are reimbursed less than their costs, they may decline to stock the drug or offer it to patients, even those covered by Medicare, Medicaid, or private insurance. This essentially blocks the therapy from reaching the market for a large portion of the patient population. For Duchenne muscular dystrophy patients and their families, who have limited treatment options, this delay is devastating. Capricor contends that unless the formula is fixed, the drug will be economically impractical to distribute, leaving patients without access to a potentially life-changing therapy.

What is deramiocel, and why is it important?

Deramiocel is an investigational cell therapy developed by Capricor Therapeutics for treating Duchenne muscular dystrophy (DMD), a severe genetic disorder that causes progressive muscle degeneration and weakness. The drug aims to slow disease progression and improve cardiac and respiratory function, addressing critical unmet needs for DMD patients. Currently, treatment options are limited, and many patients face a shortened lifespan. Deramiocel has shown promise in clinical trials, and its approval could be a major breakthrough. The dispute with Nippon Shinyaku threatens to delay its market entry, making it a high-stakes issue for the Duchenne community, which eagerly awaits new therapies.

What are the specific allegations against Nippon Shinyaku?

Capricor alleges that Nippon Shinyaku and its U.S. subsidiary NS Pharma have failed to follow through on marketing plans for deramiocel, as required by their exclusive distribution agreement. More specifically, Capricor claims that after the pricing flaw was disclosed in March 2025, Nippon Shinyaku refused to negotiate a fix, effectively slow-walking the drug’s U.S. launch. The lawsuit accuses the company of not acting in good faith and of prioritizing its own interests over patient access. Capricor also suggests that Nippon Shinyaku may be deliberately stalling to avoid or delay costs associated with a broader rollout, despite the potential harm to Duchenne patients.

What does Capricor Therapeutics want from this lawsuit?

Through the lawsuit, Capricor Therapeutics is seeking a court order to compel Nippon Shinyaku and NS Pharma to fulfill their contractual obligations, specifically to correct the pricing formula and proceed with diligent marketing efforts for deramiocel. Capricor wants the exclusive distribution agreement to be amended or enforced in a way that makes the therapy economically viable for healthcare providers and accessible to patients. The company also likely seeks damages for financial harm caused by the delay. Ultimately, Capricor aims to ensure that Duchenne patients are not left waiting because of a contractual glitch that its partner refuses to fix.